...
Autoren
zurücksetzen
...
Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

ECCEO 9-IOF, 18. - 21.03.2009, Athens, Greece.
Osteoporosis Int. 2009; 20 (Suppl. 1): S112 (Abstract P320).

Interessenskonflikte: The DAPI received financial support for this study from Procter and Gamble Pharmaceuticals; Moehrke W. employee Procter and Gamble Pharmaceuticals; Hadji P. consultant for Procter and Gamble Pharmaceuticals.